Results 11 to 20 of about 3,631,955 (312)

COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. [PDF]

J Allergy Clin Immunol, 2021
Background As of November 2020, severe acute respiratory syndrome coronavirus 2 has resulted in 55 million infections worldwide and more than 1.3 million deaths from coronavirus disease 2019 (COVID-19).
Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium.   +4 more
europepmc   +4 more sources

Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy). [PDF]

Front Cell Infect Microbiol
The gut microbiota serves a crucial role in the development of host immunity. Immunocompromised patients are particularly vulnerable to dysbiosis not only by virtue of a defect in the immune system but also due to increased susceptibility to infection ...
Napiórkowska-Baran K, Biliński J, Pujanek M, Hałakuc P, Pietryga A, Szymczak B, Deptuła A, Rosada T, Bartuzi Z.   +8 more
europepmc   +4 more sources

Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. [PDF]

Eur J Haematol, 2019
Despite long‐standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B‐cell lymphoproliferative diseases are limited.
Na IK, Buckland M, Agostini C, Edgar JDM, Friman V, Michallet M, Sánchez-Ramón S, Scheibenbogen C, Quinti I.   +8 more
europepmc   +4 more sources

Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms. [PDF]

J Am Soc Nephrol, 2022
Kidney disease is a known risk factor for poor outcome of COVID-19 and many other serious infections. Vice versa, infection ranks second as cause of death in patients with kidney disease.
Steiger S, Rossaint J, Zarbock A, Anders HJ.   +3 more
europepmc   +2 more sources

Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. [PDF]

Clin Exp Immunol, 2022
In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment.
Shields AM, Anantharachagan A, Arumugakani G, Baker K, Bahal S, Baxendale H, Bermingham W, Bhole M, Boules E, Bright P, Chopra C, Cliffe L, Cleave B, Dempster J, Devlin L, Dhalla F, Diwakar L, Drewe E, Duncan C, Dziadzio M, Elcombe S, Elkhalifa S, Gennery A, Ghanta H, Goddard S, Grigoriadou S, Hackett S, Hayman G, Herriot R, Herwadkar A, Huissoon A, Jain R, Jolles S, Johnston S, Khan S, Laffan J, Lane P, Leeman L, Lowe DM, Mahabir S, Lochlainn DJM, McDermott E, Misbah S, Moghaddas F, Morsi H, Murng S, Noorani S, O'Brien R, Patel S, Price A, Rahman T, Seneviratne S, Shrimpton A, Stroud C, Thomas M, Townsend K, Vaitla P, Verma N, Williams A, Burns SO, Savic S, Richter AG.   +61 more
europepmc   +2 more sources

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. [PDF]

Front Immunol, 2021
Secondary immunodeficiency is reported in most patients with hematological malignancies such as chronic lymphocytic leukemia and multiple myeloma.
Allegra A, Tonacci A, Musolino C, Pioggia G, Gangemi S.   +4 more
europepmc   +2 more sources

Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. [PDF]

CNS Drugs, 2021
Secondary immunodeficiencies (SIDs) are acquired conditions that may occur as sequelae of immune therapy. In recent years a number of disease-modifying therapies (DMTs) has been approved for multiple sclerosis and related disorders such as neuromyelitis ...
Szepanowski F, Warnke C, Meyer Zu Hörste G, Mausberg AK, Hartung HP, Kleinschnitz C, Stettner M.   +6 more
europepmc   +2 more sources

A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency. [PDF]

Infect Dis Ther, 2021
Vaccine-preventable diseases and their related complications are associated with increased morbidity and mortality in patients with altered immunocompetence.
Righi E, Gallo T, Azzini AM, Mazzaferri F, Cordioli M, Merighi M, Tacconelli E.   +6 more
europepmc   +2 more sources

Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China. [PDF]

Med Sci Monit, 2021
Background Infections are the main cause of mortality and morbidity in multiple myeloma (MM) patients. However, adult immunodeficiency specialists in China are lacking, and the care of secondary immunodeficiency (SID) and the prognostic role of ...
Ye C, Chen W, Gao Q, Chen Y, Song X, Zheng S, Liu J.   +6 more
europepmc   +2 more sources

Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies [PDF]

eJHaem, 2023
Secondary immunodeficiency (SID), manifesting as increased susceptibility to infection, is an emergent clinical problem in haematoncology. Management of SID includes vaccination, prophylactic antibiotics (pAbx) and immunoglobulin replacement therapy ...
Adrian M. Shields, Sian E. Faustini, Siobhan Young, Sarah Terjesen, Nicholas I. McCarthy, Rachel L. Anderson, Mark T. Drayson, Alex G. Richter   +7 more
doaj   +2 more sources